Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CALC
CALCIMEDICA, INC.
NASDAQ
$0.46
▼ DOWN 1.19% (-0.01)

KEY STATISTICS

Market Cap$7.31 M
52w High$7.20
52w Low$0.44
Dividend Yield—
Frequency—
P/E-0.35
Volume673.78K
Shares Out.15.74M

COMPANY

LEADERSHIP

A. Rachel Leheny
CHIEF EXECUTIVE
A. Rachel Leheny

COMPENSATION 2026

Salary$427,350
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$3,575
Total$895,410

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 14, 2023
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
16

PRICE TARGET

Target High$392.00
Target Low$14.00
Target Median$392.00
Target Consensus$266.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2026-08-31Reverse1:5
2023-03-20Reverse1:14

PRICE

$0.46 ▼ DOWN 1.19% (−$0.01)
OVERLAYS
$0.44$0.45$0.46$0.479:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.46

About CalciMedica, Inc.

https://www.calcimedica.com ↗

CalciMedica, Inc. is a La Jolla-based biotech company developing CRAC channel inhibitors like Auxora to treat severe inflammatory diseases such as acute pancreatitis and kidney injury.

INDUSTRY

Biotechnology

A PRODUCT CALCIMEDICA, INC. IS KNOWN FOR

Auxora™ (zegocractin)
Auxora™ (zegocractin)

Auxora™ is CalciMedica's IV small molecule CRAC channel inhibitor in clinical trials for treating severe inflammatory diseases like acute pancreatitis, with a pivotal trial underway after successful Phase 2 studies.

COMPETITORS

COMPETITOR
APGE COMPARE
CTSO COMPARE
IFRX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 89.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
23.78%
HOLDERS
46
TOP 12 OF 46 · RANKED BY POSITION SIZE
Deerfield Management Company, L.P. (Series C)
1.3M sh · $8.57M
Soleus Capital Management, L.P.
683.9K sh · $4.51M
Aisling Capital Management LP
521.1K sh · $3.43M
Vanguard Group Inc
407.8K sh · $2.69M
Jane Street Group, LLC
178.5K sh · $96.4K
Renaissance Technologies LLC
128.1K sh · $69.16K
180 Wealth Advisors, LLC
126.5K sh · $68.31K
Geode Capital Management, LLC
123.4K sh · $66.65K
Boothbay Fund Management, LLC
76.9K sh · $506.47K
Envestnet Asset Management Inc
76.7K sh · $235.93K
Meritage Portfolio Management
61.5K sh · $189.28K
Cambridge Investment Research Advisors, Inc.
60.0K sh · $32K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
10 PERCENT OWNER
ALAFI CAPITAL CO LLC
Purchase · 3.5M shares
2026-08-19
★
10 PERCENT OWNER
ALAFI CAPITAL CO LLC
Purchase · 3.5M shares
2026-08-19
★
DIRECTOR
Shaw Allan
Purchase · 10.0K shares
2026-08-19
★
DIRECTOR
Guerard Frederic
Purchase · 10.0K shares
2026-08-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
NEUTRAL 1
2 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM HC Wainwright & Co. NEUTRAL

SECTORS PEERS

PEERPRICE
RNXT$1.67COMPARE
XLO$9.00COMPARE
ELUT$0.88COMPARE
LTRN$2.07COMPARE
TVRD$1.82COMPARE
PDSB$0.21COMPARE
RVPH$0.52COMPARE